NCT00909025 - Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Solid Tumors

Interventions

DRUG

Claudiximab

"Patients receive Claudiximab as intravenous infusion over 2 hours on day 1. Cohorts of 3-6 patients receive escalating doses of Claudiximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no dose-limiting toxicity (DLT) is diagnosed in 3 patients or no more than 1 out of 6 patients exhibits a DLT.~After completion of study treatment, patients are followed for 4 weeks."

Trial Locations (6)

1002

Pauls Stradins University, Riga

3401

Piejuras Hospital, Liepāja

45122

Universitätsklinikum Essen, Innere Klinik (Tumorforschung), Essen

55131

Johannes Gutenberg Universität, 1.Med Klinik und Poliklinik, Mainz

69120

Universität Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg

81674

Klinikum Rechts-der-Isar, III.Medizinische Klinik und Poliklinik, München